Iovance (NASDAQ:IOVA) inks an agreement with Cellectis (NASDAQ:CLLS) for exclusive global rights to its TALEN gene-editing technology aimed at developing genetically edited tumor infiltrating lymphocytes (TIL) that are more effective at treating cancer.
Under the terms of the deal, Iovance will pay Cellectis undisclosed milestones and royalties on net sales of TALEN-modified TIL products. Specific financial terms remain confidential.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.